Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on priorendocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial. SABCS 2021.
